0001062993-15-006347.txt : 20151119
0001062993-15-006347.hdr.sgml : 20151119
20151119184828
ACCESSION NUMBER: 0001062993-15-006347
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151117
FILED AS OF DATE: 20151119
DATE AS OF CHANGE: 20151119
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0000875622
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 113054851
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 WILBUR ST
CITY: LYNBROOK
STATE: NY
ZIP: 11563
BUSINESS PHONE: 5165937000
MAIL ADDRESS:
STREET 1: 35 WILBUR STREET
CITY: LYNBROOK
STATE: NY
ZIP: 11563
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wegman Thomas
CENTRAL INDEX KEY: 0001355189
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34236
FILM NUMBER: 151244695
MAIL ADDRESS:
STREET 1: 1764 BRIAR PLACE
CITY: MERRICK
STATE: NY
ZIP: 11566
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2015-11-17
0000875622
BIOSPECIFICS TECHNOLOGIES CORP
BSTC
0001355189
Wegman Thomas
C/O BIOSPECIFICS TECHNOLOGIES CORP.,
35 WILBUR STREET
LYNBROOK
NY
11563
1
1
1
0
President & CEO
Common Stock, $0.001 par value
2015-11-17
4
S
0
849
50
D
146822
D
Common Stock, $0.001 par value
2015-11-18
4
S
0
10000
50.0892
D
136822
D
All shares sold at $50. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The selling price of $50.0892 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $50.00 to $50.15. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price
/s/ Carl A. Valenstein, attorney-in-fact for Thomas Wegman
2015-11-19